Artiva Biotherapeutics (NASDAQ:ARTV) Director Ra Capital Management, L.P. Buys 15,414 Shares

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Director Ra Capital Management, L.P. bought 15,414 shares of Artiva Biotherapeutics stock in a transaction dated Monday, June 15th. The stock was acquired at an average cost of $8.99 per share, with a total value of $138,571.86. Following the transaction, the director owned 16,638,150 shares of the company’s stock, valued at $149,576,968.50. This trade represents a 0.09% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Ra Capital Management, L.P. also recently made the following trade(s):

• On Tuesday, June 16th, Ra Capital Management, L.P. bought 124,893 shares of Artiva Biotherapeutics stock. The stock was acquired at an average cost of $8.89 per share, with a total value of $1,110,298.77.
• On Friday, June 12th, Ra Capital Management, L.P. bought 391,019 shares of Artiva Biotherapeutics stock. The stock was acquired at an average cost of $8.57 per share, with a total value of $3,351,032.83.
• On Thursday, June 11th, Ra Capital Management, L.P. bought 548,580 shares of Artiva Biotherapeutics stock. The stock was acquired at an average cost of $7.91 per share, with a total value of $4,339,267.80.
• On Wednesday, June 10th, Ra Capital Management, L.P. bought 103 shares of Artiva Biotherapeutics stock. The stock was acquired at an average cost of $7.00 per share, with a total value of $721.00.
• On Tuesday, June 9th, Ra Capital Management, L.P. bought 479,039 shares of Artiva Biotherapeutics stock. The stock was acquired at an average cost of $6.91 per share, with a total value of $3,310,159.49.
• On Monday, May 11th, Ra Capital Management, L.P. bought 6,510,416 shares of Artiva Biotherapeutics stock. The stock was acquired at an average cost of $11.52 per share, with a total value of $74,999,992.32.

Artiva Biotherapeutics Stock Performance

Shares of Artiva Biotherapeutics stock opened at $8.91 on Wednesday. The firm has a 50-day moving average of $9.02 and a 200-day moving average of $6.23. The stock has a market cap of $220.26 million, a PE ratio of -2.52 and a beta of 2.38. Artiva Biotherapeutics, Inc. has a 52-week low of $1.47 and a 52-week high of $14.53.

Artiva Biotherapeutics (NASDAQ:ARTV) last announced its earnings results on Friday, May 8th. The company reported ($0.95) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.07). Equities research analysts predict that Artiva Biotherapeutics, Inc. will post -2.45 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

ARTV has been the subject of a number of analyst reports. Wedbush boosted their price target on Artiva Biotherapeutics from $23.00 to $40.00 and gave the company an “outperform” rating in a research note on Monday, May 11th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Artiva Biotherapeutics in a research note on Tuesday, May 26th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Artiva Biotherapeutics in a research note on Friday, April 24th. HC Wainwright boosted their price target on Artiva Biotherapeutics from $15.00 to $35.00 and gave the company a “buy” rating in a research note on Friday, May 8th. Finally, Wall Street Zen downgraded Artiva Biotherapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, May 17th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $39.00.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of ARTV. Citadel Advisors LLC raised its stake in Artiva Biotherapeutics by 419.3% during the third quarter. Citadel Advisors LLC now owns 798,397 shares of the company’s stock worth $2,291,000 after acquiring an additional 644,658 shares in the last quarter. BNP Paribas Financial Markets raised its stake in Artiva Biotherapeutics by 14,463.5% during the third quarter. BNP Paribas Financial Markets now owns 118,547 shares of the company’s stock worth $340,000 after acquiring an additional 117,733 shares in the last quarter. Marshall Wace LLP acquired a new position in Artiva Biotherapeutics during the fourth quarter worth about $341,000. Jane Street Group LLC acquired a new position in Artiva Biotherapeutics during the second quarter worth about $67,000. Finally, Landscape Capital Management L.L.C. acquired a new position in Artiva Biotherapeutics during the third quarter worth about $112,000.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.